Second Genome Scores A Deal With Janssen, A First In The Field Of Microbiome Therapeutics

Second Genome’s ulcerative colitis research alliance with Janssen Biotech is a first in the burgeoning microbiome therapeutics space, which may be transitioning from venture investment to commercial partnering. But is the deal an inflection point or a fluke?